Browse Category

Stock Market News 13 January 2026

ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow shares fell 3.3% to $137.95 Tuesday after Oppenheimer cut its price target to $200, citing sector concerns ahead of earnings. Goldman Sachs began coverage with a Buy rating and $205 target, while Citi maintained its Buy and placed the stock on a 30-day catalyst watch. The iShares Expanded Tech-Software ETF dropped 2%. Investors remain cautious after ServiceNow’s $7.75 billion Armis acquisition.
Ofwat warns on South East Water outage as Severn Trent, United Utilities shares fall

Ofwat warns on South East Water outage as Severn Trent, United Utilities shares fall

Around 25,000 homes in Kent and Sussex lost water after a new supply failure at South East Water, prompting Ofwat to flag concern and launch a review. Shares in Severn Trent, United Utilities, and Pennon fell up to 2.6% as scrutiny intensified. South East Water is using tankers and bottled-water stations while restoring pressure, with full service expected by Wednesday. Some homes have faced four days without water.
13 January 2026
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam shares fell 0.1% to $370.39 Tuesday afternoon after the company projected 2026 net product revenue between $4.9 billion and $5.3 billion. Preliminary 2025 sales were disclosed at $2.987 billion. Analysts remained mostly positive but flagged possible weakness for Amvuttra next quarter. The update came as Alnylam outlined its new five-year strategy at the J.P. Morgan Healthcare Conference.
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola shares rose 0.5% to $70.83 Tuesday after the company set Feb. 10 for its Q4 and full-year earnings release and investor call. CEO-elect Henrique Braun and CFO John Murphy will speak at the CAGNY conference in Orlando on Feb. 17. Coke expects a $1 billion impairment charge in Q4 tied to its Africa bottling sale. PepsiCo shares gained 1.4% while the S&P 500 ETF slipped 0.4%.
American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

American Airlines shares fell 3.5% to $15.44 Tuesday, underperforming other major U.S. carriers as investors reacted to Delta’s profit forecast and concerns over a proposed 10% cap on credit-card interest rates. The cap could threaten airline loyalty program profits. American will report earnings Jan. 27, the same day the NTSB holds a hearing on a 2025 fatal crash involving one of its regional jets.
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics shares fell 19% Tuesday after the FDA extended its review of Filspari for broader use in kidney disease, pushing the decision deadline to April 13. The stock hit an intraday low of $22.35 before recovering. Travere forecast $127 million in Q4 U.S. net product sales and ended 2025 with $323 million in cash and equivalents. Analyst Joseph Schwartz warned a formal rejection from the FDA remains possible.

Stock Market Today

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

7 February 2026
IRS staffing has dropped to 2021 levels as the 2026 tax filing season begins, according to a Treasury watchdog. The agency faces a backlog of about 2 million returns, 129% above pre-pandemic levels. Most e-filers using direct deposit still get refunds within 21 days, but paper filings and amended returns could see delays. The IRS lowered its call-answer target to 70% for this season.
Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

7 February 2026
Plug Power shares rose 11.6% Friday to $2.08 after a sharp drop the previous day, as attention shifted to a Feb. 17 shareholder vote on expanding authorized shares. The company failed to secure enough votes earlier this week and is urging overseas holders to participate. CEO Andy Marsh cited difficulties for European investors in casting ballots. A reverse stock split remains possible if the proposal fails.
AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

7 February 2026
AT&T shares closed down 0.7% at $27.13 on Friday, underperforming the S&P 500’s 1.97% gain. The company completed a $6.5 billion global notes sale this week, with maturities from 2031 to 2056 and coupons between 4.4% and 6%. Investors await delayed U.S. jobs and inflation data, along with T-Mobile’s upcoming earnings update.
Go toTop